{"id":"NCT01021332","sponsor":"Astellas Pharma Europe B.V.","briefTitle":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","officialTitle":"An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04-26","primaryCompletion":"2011-12-14","completion":"2011-12-14","firstPosted":"2009-11-26","resultsPosted":"2016-01-22","lastUpdate":"2024-12-03"},"enrollment":1067,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lower Urinary Tract Symptoms","Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)","otherNames":["EC905","Vesomni"]},{"type":"DRUG","name":"tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)","otherNames":["EC905"]}],"arms":[{"label":"Total Group","type":"EXPERIMENTAL"}],"summary":"Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From first dose of double-blind study drug (if on FDC in 905-CL-055) or first open-label dose up to 30 days after last dose of open-label study drug (in 905-CL-057) (up to 56 weeks)","effectByArm":[{"arm":"Total Group","deltaMin":499,"sd":null}],"pValues":[]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":70,"countries":["Austria","Belarus","Belgium","Czechia","France","Germany","Italy","Netherlands","Poland","Slovakia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=39"]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":1066},"commonTop":["Dry Mouth","Constipation"]}}